Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.06 USD
-0.04 (-3.64%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $1.06 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Iterum Therapeutics PLC [ITRM]
Reports for Purchase
Showing records 61 - 73 ( 73 total )
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem Narrowly Misses in cIAI But We See Larger Value in UTI; Moderate PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Top-line Results of SURE 2 in cUTI on Track for 1Q20; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
3Q19 Recap First Pivotal Readout in cIAI Around Year-End 2019; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
2Q Recap Major Near-Term Catalyst in Phase 3 Topline Expected 4Q19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
We Highlight Several Antibiotics at the ASM Microbe 2019 Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Not Just Another Antibiotic Company; Initiate Buy Ahead of Three Phase 3 Readouts
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E